Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib and Cetuximab Window of Opportunity Study in Head and Neck Cancer
NCT05816785Phase 1Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Apr 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of imatinib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by University of Wisconsin–Madison. Primary endpoint: Change in Ki67 from pre- versus post-imatinib/cetuximab treated tumors. Started Apr 2023; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05816785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05816785.